No­var­tis bets PRV on its next big mul­ti­ple scle­ro­sis drug — eyes US, EU ap­provals in '19

One of No­var­tis’ top late-stage can­di­dates for mul­ti­ple scle­ro­sis is now un­der re­view on both sides of the At­lantic.

Hav­ing stoked en­thu­si­asm for sipon­i­mod through a sol­id Phase III da­ta pack­age, the Swiss drug­mak­er trad­ed in a pri­or­i­ty re­view vouch­er at the FDA for an ex­pe­dit­ed ac­tion date around March of next year. The EMA de­ci­sion, mean­while, will like­ly come in late 2019.

If No­var­tis ap­pears up­beat, it’s for ob­vi­ous rea­sons.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.